Selective modulation of superantigen-induced responses by streptococcal cysteine protease

Journal of Infectious Diseases

Volumn 187, Issue 3, 2003, Pages 398-407

  Kansal, Rita G ^a   Nizet, Victor ^b   Jeng, Arthur ^c   Chuang, Woei Jer ^d   Kotb, Malak ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AGMATINE; CYSTEINE PROTEINASE; EXOTOXIN; N [N (3 CARBOXYOXIRANE 2 CARBONYL)LEUCYL]AGMATINE; STREPTOCOCCAL PYROGENIC EXOTOXIN; SUPERANTIGEN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ARTICLE; BACTERIAL VIRULENCE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOMODULATION; INFLAMMATION; LYMPHOCYTE ACTIVATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; STREPTOCOCCUS GROUP A;

BACTERIAL PROTEINS; CELL DIVISION; CULTURE MEDIA, CONDITIONED; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; HUMANS; LEUCINE; LYMPHOCYTES; STREPTOCOCCUS; SUPERANTIGENS;

EID: 0037312503     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/368022     Document Type: Article

References (30)

1. Low DE, Schwartz B, McGeer A. The re-emergence of severe group A streptococcal disease: an evolutionary perspective. Emerg Pathog 1997; 1:93-123.
2. Kotb M. Bacterial pyrogenic exotoxins as superantigens. Clin Microbiol Rev 1995; 8:411-26.
3. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 2000; 13:470-511.
4. Norrby-Teglund A, Kotb M. Host-microbe interactions in the pathogenesis of invasive group A streptococcal infections. J Med Microbiol 2000; 49:849-52.
5. Berge A, Bjorck L. Streptococcal cysteine proteinase releases biologically active fragments of streptococcal surface proteins. J Biol Chem 1995; 270:9862-7.
6. Schlievert PM, Assimacopoulos AP, Cleary PP. Severe invasive group A streptococcal disease: clinical description and mechanisms of pathogenesis. J Lab Clin Med 1996; 127:13-22.
7. Chatellier S, Ihendyane N, Kansal RG, et al. Genetic relatedness and superantigen expression in group A streptococcus serotype M1 isolates from patients with severe and nonsevere invasive diseases. Infect Immun 2000; 68:3523-34.
8. Kansal RG, McGeer A, Low DE, Norrby-Teglund A, Kotb M. Inverse relation between disease severity and expression of the streptococcal cysteine protease, SpeB, among clonal M1T1 isolates recovered from invasive group A streptococcal infection cases. Infect Immun 2000; 68: 6362-9.
9. Kazmi SU, Kansal R, Aziz RK, et al. Reciprocal, temporal expression of SpeA and SpeB by invasive M1T1 group a streptococcal isolates in vivo. Infect Immun 2001; 69:4988-95.
10. Burns EH Jr, Marciel AM, Musser JM. Activation of 66-kilodalton human endothelial cell matrix metalloprotease by Streptococcus pyogenes extracellular cysteine protease. Infect Immun 1996; 64:4744-50.
11. Herwald H, Collin M, Muller-Esterl W, Bjorck L. Streptococcal cysteine proteinase releases kinins: a virulence mechanism. J Exp Med 1996; 184:665-73.
12. Kapur V, Majesky MW, Li L-L, Black RA, Musser JM. Cleavage of interleukin 1β (IL-1β) precursor to produce active IL 1-β by a conserved extracellular cysteine protease from Streptococcus pyogenes. Proc Natl Acad Sci USA 1993;90:7676-80.
13. Kaput V, Topouzis S, Majesky MW, et al. A conserved Streptococcus pyogenes extracellular cysteine protease cleaves human fibronectin and degrades vitronectin. Microb Pathog 1993; 15:327-46.
14. Wolf BB, Gibson CA, Kapur V, Hussaini IM, Musser JM, Gonias SL. Proteolytically active streptococcal pyrogenic exotoxin B cleaves monocytic cell urokinase receptor and releases an active fragment of the receptor from the cell surface. J Biol Chem 1994; 269:30682-7.
15. Chaussee MS, Cole RL, van Putten JP. Streptococcal erythrogenic toxin B brogates fibronectin-dependent internalization of Streptococcus pyogenes by cultured mammalian cells. Infect Immun 2000; 68:3226-32.
16. Raeder R, Woischnik M, Podbielski A, Boyle MD. A secreted streptococcal cysteine protease can cleave a surface-expressed M1 protein and alter the immunoglobulin binding properties. Res Microbiol 1998; 149:539-48.
17. Raeder R, Harokopakis E, Hollingshead S, Boyle MD. Absence of SpeB production in virulent large capsular forms of group A streptococcal strain 64. Infect Immun 2000; 68:744-51.
18. Rasmussen M, Bjorck L. Proteolysis and its regulation at the surface of Streptococcus pyogenes. Mol Microbiol 2002; 43:537-44.
19. Lukomski S, Montgomery CA, Rurangirwa J, et al. Extracellular cysteine protease produced by Streptococcus pyogenes participates in the pathogenesis of invasive skin infection and dissemination in mice. Infect Immun 1999; 67:1779-88.
20. Lukomski S, Sreevatsan S, Amberg C, et al. Inactivation of Streptococcus pyogenes extracellular cysteine protease significantly decreases mouse lethality of serottype M3 and M49 strains. J Clin Invest 1997;99:2574-80.
21. Lukomski S, Burns EH Jr, Wyde PR, et al. Genetic inactivation of an extracellular cysteine protease (SpeB) expressed by Streptococcus pyogenes decreases resistance to phagocytosis and dissemination to organs Infect Immun 1998; 66:771-6.
22. Ashbaugh CD, Wessels MR. Absence of a cysteine protease effect on bacterial virulence in two murine models of human invasive group A streptococcal infection. Infect Immun 2001; 69:6683-8.
23. Framson PE, Nittayajarn A, Merry J, Youngman P, Rubens CE. New genetic techniques for group B streptococci: high-efficiency transformation, maintenance of temperature-sensitive pWV01 plasmids, and mutagenesis with Tn917. Appl Environ Microbiol 1997; 63:3539-47.
24. Norrby-Teglund A, Kaul R, Low DE, et al. Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production. J Immunol 1996; 156:3057-64.
25. Proft T, Moffatt SL, Berkahn CJ, Fraser JD. Identification and characterization of novel superantigens from Streptococcus pyogenes. J Exp Med 1999; 189:89-102.
26. Kotb M. Role of superantigens in the pathogenesis of infectious diseases and their sequelae. Curr Opin Infect Dis 1992; 5:364-74.
27. Norrby-Teglund A, Chatellier S, Low DE, McGeer A, Green K, Kotb M. Host variation in cytokine responses to superantigens determine the severity of invasive group A streptococcal infection. Eur J Immunol 2000; 30:3247-55.
28. Proft T, Moffatt SL, Weller KD, Paterson A, Martin D, Fraser JD. The streptococcal superantigen SMEZ exhibits wide allelic variation, mosaic structure, and significant antigenic variation. J Exp Med 2000; 191: 1765-76.
29. von Pawel-Rammingen U, Johansson BP, Bjorck L. IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G. EMBO J 2002; 21:1607-15.
30. Unnikrishnan M, Altmann DM, Proft T, et al. The bacterial superantigen streptococcal mitogenic exotoxin Z is the major immunoactive agent of Streptococcus pyogenes. J Immunol 2002; 169:2561-9.